Genmab — Oktober 2014
-
Strohl said one of the difficulties in developing bispecific antibodies is overcoming manufacturing hurdles. “Most can’t be manufactured,” he said. “I have to say we were a little frustrated that we couldn’t develop, internally, a technology that could be trusted to be manufacturable.”
Genmab’s technology proved to be the most promising solution. “We now have 20 bispecific licenses with them,” Strohl said.
-
-
jeg tager det stadig forholdsvis roligt
-
anonyme køber stadig ind
-
de har normalt ingen løbetid på. men de betaler jo en rente for at låne aktierne
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind